Niu Qifang, Yang Yang, Li Delong, Guo Wenwen, Wang Chong, Xu Haoyue, Feng Zhien, Han Zhengxue
Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing 100050, China.
Department of Oral and Maxillofacial Surgery, Beijing XingYe Stomatological Hospital, Beijing 102600, China.
Life (Basel). 2022 Oct 9;12(10):1567. doi: 10.3390/life12101567.
Free tissue flap transplantation is a classic and important method for the clinical repair of tissue defects. However, ischemia-reperfusion (IR) injury can affect the success rate of skin flap transplantation. We used a free abdomen flap rat model to explore the protective effects of exosomes derived from bone marrow mesenchymal stem cells (BMSCs-exosomes) against the IR injury of the skin flap. Exosomes were injected through the tail vein and the flaps were observed and obtained on day 7. We observed that BMSCs-exosomes significantly reduced the necrotic lesions of the skin flap. Furthermore, BMSCs-exosomes relieved oxidative stress and reduced the levels of inflammatory factors. Apoptosis was evaluated via the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and Western blot analysis of Bax, Bcl-2. Simultaneously, BMSCs-exosomes promoted the formation of new blood vessels in the IR flap, as confirmed by the increased expression level of VEGFA and the fluorescence co-staining of CD31 and PCNA. Additionally, BMSCs-exosomes considerably increased proliferation and migration of human umbilical vein endothelial cells and promoted angiogenesis in vitro. BMSCs-exosomes could be a promising cell-free therapeutic candidate to reduce IR injury and promote the survival of skin flaps.
游离组织瓣移植是临床上修复组织缺损的经典且重要的方法。然而,缺血再灌注(IR)损伤会影响皮瓣移植的成功率。我们使用游离腹部皮瓣大鼠模型来探究骨髓间充质干细胞来源的外泌体(BMSCs-外泌体)对皮瓣IR损伤的保护作用。通过尾静脉注射外泌体,并在第7天观察和获取皮瓣。我们观察到BMSCs-外泌体显著减少了皮瓣的坏死病变。此外,BMSCs-外泌体减轻了氧化应激并降低了炎症因子水平。通过末端脱氧核苷酸转移酶dUTP缺口末端标记(TUNEL)测定法以及Bax、Bcl-2的蛋白质免疫印迹分析来评估细胞凋亡。同时,BMSCs-外泌体促进了IR皮瓣中新生血管的形成,这通过VEGFA表达水平的升高以及CD31和PCNA的荧光共染色得以证实。此外,BMSCs-外泌体显著增加了人脐静脉内皮细胞的增殖和迁移,并在体外促进了血管生成。BMSCs-外泌体可能是一种有前景的无细胞治疗候选物,可减少IR损伤并促进皮瓣存活。